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Abstract
Mutations in AIPL1 cause the inherited blindness Leber congenital amaurosis (LCA). AIPL1 has previously been shown to
interact with NUB1, which facilitates the proteasomal degradation of proteins modified with the ubiquitin-like protein
FAT10. Here we report that AIPL1 binds non-covalently to free FAT10 and FAT10ylated proteins and can form a ternary
complex with FAT10 and NUB1. In addition, AIPL1 antagonised the NUB1-mediated degradation of the model FAT10
conjugate, FAT10-DHFR, and pathogenic mutations of AIPL1 were defective in inhibiting this degradation. While all AIPL1
mutants tested still bound FAT10-DHFR, there was a close correlation between the ability of the mutants to interact with
NUB1 and their ability to prevent NUB1-mediated degradation. Interestingly, AIPL1 also co-immunoprecipitated the E1
activating enzyme for FAT10, UBA6, suggesting AIPL1 may have a role in directly regulating the FAT10 conjugation
machinery. These studies are the first to implicate FAT10 in retinal cell biology and LCA pathogenesis, and reveal a new role
of AIPL1 in regulating the FAT10 pathway.
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Introduction
Mutations in the retina and pineal-specific aryl hydrocarbon
receptor interacting protein-like 1 (AIPL1) lead to the inherited
blindness Leber congenital amaurosis (LCA), which is charac-
terised by severe vision loss or blindness at birth [1]. AIPL1 has
been proposed to act as a specialized chaperone for the cGMP
phosphodiesterase PDE6 [2,3,4] and interacts with Hsp70 and
Hsp90 family members to form a chaperone heterocomplex [5],
but the precise role of AIPL1 in the retina has yet to be fully
elucidated. AIPL1 was also reported to interact with NEDD8
ultimate buster-1 (NUB1) [6], which promotes the proteasomal
degradation of the ubiquitin-like modifiers (UBLs) NEDD8 and
FAT10 and their modification targets [7,8], thus implicating
AIPL1 in photoreceptor protein degradation pathways. AIPL1 has
previously been shown to modulate NUB1 nuclear translocation
and suppress the aggregation of NUB1 fragments [9], but the
precise functional relationship between these two proteins has
remained unknown.
Modification of proteins by ubiquitin and UBLs controls a
diverse array of cellular processes through altering protein
interactions, function and degradation [10]. Conjugation of UBLs
to their targets is a multi-step process involving several sequential
steps. Firstly, an E1 activating enzyme adenylates the conserved C-
terminal diglycine motif of the UBL, followed quickly by the
formation of a high-energy thioester between the UBL and the E1
active-site cysteine. The charged UBL is then passed to the active-
site cysteine of a specific E2 conjugating enzyme to form a second
thioester bond. Finally, the E2 enzyme coordinates with a
substrate-bound E3 ligase to covalently conjugate the UBL onto
an internal lysine in the substrate through an isopeptide bond [10].
FAT10 is a member of the family of UBL modifiers [11]. It
contains two UBL domains separated by a short linker, with 29%
and 36% identity to ubiquitin respectively, and is conjugated onto
a lysine residue in the target protein through its C-terminal
diglycine motif [11]. FAT10 is a ubiquitin-independent signal for
proteasomal degradation [12,13], but other than autoFAT10yla-
tion of the recently characterised FAT10 E2 enzyme USE1 [14],
the physiological substrates for FAT10 modification are currently
unidentified. NUB1 and NUB1L (a longer splice variant of NUB1)
were found to interact with and promote the proteasomal
degradation of FAT10 and FAT10-modified proteins [7,15].
NUB1L contains three tandem ubiquitin-associated (UBA)
domains toward its C-terminus and a single UBL domain near
the N-terminus, whereas NUB1 lacks 14 amino acids in the second
UBA domain such that it has only two UBA domains. NUB1 and
NUB1L have been shown to bind the 26S proteasome through
their single UBL domain and bind FAT10 through their UBA
domains, and thus act on the proteasome to facilitate the
degradation of FAT10-modified proteins [15]. Indeed, NUB1L
has been shown to be essential for the degradation of FAT10-
fusion proteins in vitro [13].
While the E1 activating enzyme for FAT10 has been identified
as UBA6 (E1-L2) [16] and USE1 has recently been described as an
E2 conjugating enzyme [14], no other components of the FAT10
conjugation machinery or physiological substrates have thus far
been reported, other than autoFAT10ylation of USE1 [14]. A role
for FAT10 in the mammalian immune system has been proposed
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as it is enriched in the thymus and spleen [17], its expression is
induced by IFN-gamma and TNF-alpha, and FAT10 knockout
mice display hypersensitivity to endotoxin challenge [18]. FAT10
has also been implicated in apoptosis [11], various cancers [19,20]
as well as in the cellular response to misfolded protein
accumulation [21], but the precise physiological functions of
FAT10 have not yet been demonstrated. FAT10 has also been
shown to interact with, and prevent, MAD2 association with
kinetochores [17,22], suggesting the biological role of FAT10
modification may extend beyond protein degradation.
Here, we report that the photoreceptor-specific protein AIPL1 is
a novel regulator of the FAT10 pathway. We demonstrate that
AIPL1 acts to antagonise NUB1-mediated degradation of the model
FAT10 substrate FAT10-DHFR, and that pathogenic mutations
are defective in this function. In summary, these studies highlight a
previously unidentified role of the FAT10 pathway in photoreceptor
cell biology with implications in the pathogenesis of LCA.
Materials and Methods
Antibodies
Rabbit polyclonal antibodies to AIPL1, NUB1 and FAT10 were
described previously [9,12,23,24,25]. Mouse monoclonal anti-HA
(purified immunoglobulin, H3663), anti-polyhistidine (ascites fluid,
H1029), anti-FLAG (purified immunoglobulin, F3165) and anti-c-
Myc (purified immunoglobulin, M4439) antibodies were pur-
chased from Sigma (St. Louis, MO), and goat polyclonal anti-GST
antibody was purchased from GE Healthcare (Amersham, UK).
Horseradish peroxidise-conjugated mouse, rabbit and goat
secondary antibodies were purchased from Pierce Biotechnology
(Rockford, IL).
Plasmids
Expression plasmids p-GEXT-2T-AIPL1 (GST-AIPL1),
pCMV-Tag3C-AIPL1 (Myc-AIPL1) and pCMV-Tag3C-AIPL1
mutants A197P, C239R and G262S were described previously
[9,23], as were HA-FAT10-pCDNA3.1, HA-FAT10-AV-DHFR
[11,12], His6-UBA6-pCDNA3.1 and His6-3XFLAG-FAT10DGG
[14]. NUB1-p3XFLAG-CMV (NUB1-FLAG) was generated by
subcloning NUB1 from pEGFP-C1-NUB1 [9] into p3XFLAG-
CMV-14 vector (Sigma, St. Louis, MO) using standard methods.
Cell culture and transfection
SK-N-SH neuroblastoma cells (purchased from ATCC) were
maintained and grown as previously described [26]. Cells were
transfected 24 hours after seeding in six-well plates, using
Lipofectamine and Plus reagent according to manufacturer’s
instructions (Invitrogen, Paisley, UK). Single wells were transfected
as indicated with 900 ng HA-FAT10, His-FLAG-FAT10DGG or
HA-FAT10-DHFR, and 300 ng of NUB1-FLAG, Myc-AIPL1/
mutants and His-UBA6, and empty plasmid DNA was used to
maintain a total plasmid DNA transfection amount of 1.5 mg
where necessary. Treatment of cells with 50 mM proteasome
inhibitor MG132 (Enzo Life Sciences, Plymouth, UK) was
performed 20 hours post-transfection for 4 hours. Cycloheximide
(Sigma, St Louis, MO) treatment was performed at 50 mg/ml final
concentration 20–24 hours post-transfection for 0–4 hours.
Immunocytochemistry
SK-N-SH cells were transfected as described above. Cells were
washed with PBS 24 hours post-transfection, fixed with 4%
paraformaldehyde for 15 min, and permeabilised in 0.1% Triton-
X-100 for 5 min. Cells were incubated in block solution (10%
donkey serum in PBS) for 30 min, followed by incubation with
primary antibody anti-HA (1:150) (Sigma, St Louis, MO) in block
solution for 1 h. Primary antibody was removed followed by
465 min washes in PBS, prior to incubation with Cy2-conjugated
anti-mouse secondary (1:150) in block solution for 45 min.
Secondary antibody was removed and cells were washed 4 times
in PBS. Fluorescence was visualised using a Zeiss LSM 510 laser
scanning confocal microscope.
Western blotting and immunoprecipitation
Twenty-four hours post-transfection, cells were washed in PBS
and lysed in DM buffer (1% n-dodecyl-b-D-maltoside; 10 mM
EDTA; protease inhibitor cocktail (Sigma, St Louis, MO) in PBS)
(300 ml/well) for 15 min at 4uC. Cell lysates were denatured with
36 sample buffer (62.5 mM Tris-HCl, pH 6.8; 2.5% SDS; 5% 2-
mercaptoethanol; 10% glycerol; 0.25% bromophenol blue) and
15 ml resolved by denaturing SDS-PAGE. Transfer onto nitrocel-
lulose membrane and western blotting was carried out as
previously described [24]. For immunoprecipitation, 250 ml of
cell lysate was incubated with 2 ml of antibody for 2 hours at 4uC,
followed by addition of 50 mL of 50% slurry Protein G Sepharose
4 Fast Flow (GE Healthcare, Amersham, UK) equilibrated in DM
buffer. Following overnight incubation at 4uC, the immune
complex was thoroughly washed in ice-cold DM buffer (561 ml
washes), and proteins eluted in 50 ml sample buffer and analysed
by western blot analysis. Western blotting and immunoprecipita-
tion results were reproduced from between 2 and 7 independent
replicates per experiment. Numerical values documenting ob-
served fold changes were calculated using standard densitometric
analyses (ImageJ) from at least 3 independent experimental
replicates. Specifically, the intensity of the bands was measured
from 3 independent experiments (ImageJ) and the resultant data
normalised to the experiment-specific internal control (1 or 100%)
to calculate the fold change or change in percentage respectively.
For the cycloheximide experiment, the Wilcoxon signed-rank test
was used to calculate the level of significance of the temporal
change in FAT10 levels from 3 independent experiments (UCLA
Statistics Online Computational Resource).
Recombinant protein purification and pull-down
experiments
Expression and purification of GST and GST-AIPL1 from
Escherichia coli JM109 cells was performed as previously described
[5]. For pull-down of HA-FAT10 from transfected SK-N-SH
lysates, cells were harvested from individual wells of a six-well plate
as described above and 250 ml lysate was pre-cleared with 10 mg
GST for 2 h at 4uC. GST was removed from lysates by the
addition of 50 ml of 50% slurry Glutathione-Sepharose 4B (GE
Healthcare, Amersham, UK). Pre-cleared lysates were then
incubated with either 0.38 nmol GST or 0.38 nmol GST-AIPL1
at 4uC overnight. Bound proteins were pulled down using 50 ml of
50% slurry Glutathione-Sepharose 4B, and washed thoroughly in
ice-cold PBS (561 ml washes) before elution in 50 ml sample
buffer and western blot analysis. For pull-down of recombinant
purified His6-FAT10 (Enzo Life Sciences, Plymouth, UK),
0.38 nmol of GST or GST-AIPL1 was incubated with 0.38 nmol
His6-FAT10 in 50 mM Tris-HCL pH 6.8 at 4uC overnight, and
bound proteins were pulled down as described. Pull-down
experiments were reproduced in five independent experiments.
Results
AIPL1 alters the NUB1-mediated degradation of FAT10
NUB1, and its longer splice variant NUB1L, have previously
been shown to interact with and elicit the proteasomal degradation
AIPL1 Regulates the FAT10 Pathway
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of free FAT10 and FAT10-modified proteins [7,15]. To confirm
these findings, SK-N-SH cells [9] were transfected with HA-
FAT10 alone or with NUB1-FLAG in the presence and absence of
the proteasome inhibitor MG132. Western blot analysis revealed a
FAT10 expression profile of unconjugated FAT10, an unidentified
FAT10-conjugated protein migrating at ,36 kDa and a charac-
teristic smear of high molecular weight FAT10-modified proteins
(Figure 1A). Co-expression of NUB1 with FAT10 resulted in the
disappearance of all FAT10 species, while proteasome inhibition
reduced the NUB1-mediated degradation of FAT10 to ,70%
(73%69) of FAT10 levels alone, in agreement with NUB1’s role in
the proteasomal degradation of FAT10. To confirm the well
characterised interaction between FAT10 and NUB1, co-immu-
noprecipitation experiments were performed on cell lysates
expressing FAT10 and NUB1. Immunoprecipitation of HA-
FAT10 with anti-HA antibody confirmed that NUB1 interacts
with FAT10, and this interaction was enhanced ,5-fold when the
proteasome was inhibited with MG132 (Figure 1A). NUB1 has
been previously shown to interact with the inherited blindness
protein AIPL1 [6], and we confirmed that NUB1-FLAG co-
precipitated with myc-AIPL1 (Figure 1B) before assessing what
effect AIPL1 has on the NUB1-mediated degradation of FAT10.
SK-N-SH cells were transfected with FAT10 alone and in
combination with either AIPL1 or NUB1, then with both AIPL1
and NUB1. Interestingly, western blot analysis revealed that co-
expression of AIPL1 with FAT10 caused an ,30% (30%69)
increase in monomeric FAT10 and a similar increase in high
molecular weight FAT10-conjugated proteins, suggesting that
AIPL1 interacts with the FAT10 degradation pathway (Figure 1C).
AIPL1 also affected the NUB1-mediated degradation profile of
FAT10, whereby the steady-state levels of monomeric FAT10 and
the ,36 kDa FAT10 conjugate were increased by ,6 fold and
,5-fold respectively in the presence of AIPL1 and NUB1,
compared to NUB1 alone (Figure 1C). This suggested AIPL1
may block the NUB1-mediated degradation of FAT10ylated
proteins. Similarly, immunocytochemical analysis also revealed the
NUB1-mediated proteasomal-targeting of HA-FAT10, and the
inhibition of this NUB1-mediated FAT10 degradation by AIPL1
(Figure 1D). In denaturing western blots, an additional prominent
HA-FAT10 band of around 72 kDa was also evident in the
presence of AIPL1 and was detectable by AIPL1, HA and FAT10
antibodies, suggesting that a minor proportion of AIPL1 itself
(3.5%61) may be modified by FAT10 (Figure 1C and E, asterisk).
To confirm that this was a covalent conjugate of AIPL1-FAT10
mediated through the C-terminal diglycine motif of FAT10, we
expressed the FAT10 mutant His-FLAG-FAT10DGG and found
that AIPL1 could not be modified with this version of FAT10
under denaturing conditions (Figure 1E). Therefore, not only does
AIPL1 appear to block NUB1-mediated degradation of FAT10y-
lated proteins, but a small proportion of AIPL1 (,5%) itself is
modified with FAT10.
AIPL1 directly binds to FAT10 and interacts with high
molecular weight FAT10ylated proteins
The finding that AIPL1 increases steady-state levels of FAT10
and FAT10-modified proteins led us to investigate whether AIPL1
also interacts non-covalently with FAT10 itself. To address this,
AIPL1 was co-expressed with FAT10 and co-precipitation
experiments were performed. Monomeric FAT10 co-precipitated
specifically with AIPL1 (Figure 2A), supporting the hypothesis that
AIPL1 is in a complex with FAT10. The ability of AIPL1 to
interact non-covalently with FAT10 was not dependent on the C-
terminal diglycine motif of FAT10, as AIPL1 could also co-
precipitate a conjugation-deficient His-FLAG-FAT10DGG mu-
tant (data not shown). As AIPL1 was capable of interacting with
unconjugated FAT10, it was of interest to test whether AIPL1
would also associate with high molecular weight FAT10-modified
proteins. To test this hypothesis, glutathione-S-transferase (GST)
pull-down experiments were performed on the lysates of SK-N-SH
cells transfected with HA-FAT10 plasmid. GST-AIPL1, but not
GST, was able to pull-down free FAT10 as well as a range of high
molecular weight FAT10 species, confirming the ability of AIPL1
to interact with FAT10-modified proteins (Figure 2B). To
investigate if AIPL1 could bind directly to FAT10, GST pull-
down experiments were performed using equimolar amounts of
recombinant purified GST-AIPL1 and His6-FAT10. His6-FAT10
was specifically pulled down by GST-AIPL1, confirming that
AIPL1 and FAT10 do interact directly (Figure 2C).
AIPL1, NUB1 and FAT10 form a ternary complex
As AIPL1 binds to both NUB1 [27] (Figure 1) and FAT10
(Figure 2), we sought to investigate whether AIPL1, NUB1 and
FAT10 could form a ternary complex. To test this, combinations
of AIPL1, NUB1 and FAT10 were expressed in SK-N-SH cells
followed by co-precipitation and western blotting. AIPL1 co-
precipitated with NUB1 (Figure 3A, top panel) and vice versa
(Figure 3A, bottom panel), and this reciprocal interaction was
unaffected by FAT10 which precipitated with both AIPL1 and
NUB1 (Figure 3A). Treatment of cells with proteasome inhibitor
prevented degradation of FAT10 in the presence of NUB1 and
increased the amount of FAT10 that co-precipitated with NUB1
and AIPL1 by ,2 fold and ,5 fold respectively. Moreover,
proteasome inhibition increased the amount of AIPL1 that co-
precipitated with NUB1 by,40%, and vice versa in the reciprocal
interaction precipitation (Figure 3A). Immunoprecipitation of
FAT10 co-precipitated both AIPL1 and NUB1 (Figure 3B),
showing that regardless of which protein (AIPL1, NUB1 or
FAT10) was immunoprecipitated, the other two proteins always
co-precipitated. The mutation of cysteine 239 to arginine (C239R)
in AIPL1 causes LCA and prevents AIPL1 from binding to NUB1
[27]. This mutant was still able to bind FAT10 (Figure 3B) and
therefore could be used to test if FAT10 restores the association of
AIPL1 C239R to NUB1 through ternary complex formation.
Myc-tagged AIPL1 C329R was immunoprecipitated and shown to
be defective in its interaction with NUB1 (Figure 3C) in agreement
with previous studies [27]. However, expression of FAT10
stimulated NUB1 co-precipitation with AIPL1 C239R, strongly
suggesting the three proteins form a ternary complex (Figure 3C).
Interestingly, the C239R mutant was unable to alter the NUB1-
mediated degradation profile of FAT10 (Figure 3B), suggesting the
direct interaction of AIPL1 with NUB1 is important in modifying
FAT10 degradation.
AIPL1 antagonises the NUB1-mediated degradation of
FAT10-DHFR
AIPL1 increased the steady-state levels of FAT10 and FAT10-
modified proteins, which suggested that AIPL1 may protect
against the NUB1-mediated degradation of FAT10 substrates. To
test this hypothesis, the extent of NUB1-mediated degradation of
the model FAT10 substrate HA-FAT10-DHFR [12] in the
presence and absence of AIPL1 was examined. Post-transfection
SK-N-SH cells were treated with the translation inhibitor
cycloheximide (CHX) in order to assess FAT10-DHFR degrada-
tion. AIPL1 alone had no effect on FAT10-DHFR degradation,
whereas NUB1 was observed to increase its degradation as
expected (Figure 4A). Importantly, AIPL1 prevented FAT10-
DHFR degradation in the presence of NUB1 (Figure 4A), and this
effect was more pronounced upon treatment with proteasome
AIPL1 Regulates the FAT10 Pathway
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inhibitor MG132, demonstrating its ability to antagonise the
NUB1-mediated proteasomal degradation of a model FAT10
substrate. CHX-chase experiments were then performed to
confirm the AIPL1-mediated effects on FAT10-DHFR degrada-
tion. Although NUB1 had stimulated the degradation of most
detectable FAT10-DHFR by 2 hours CHX treatment, in the
presence of AIPL1, FAT10-DHFR was still detectable after
2 hours (,60% (64%618) FAT10-DHFR levels remaining) and
Figure 1. AIPL1 alters the NUB1-mediated degradation of FAT10. SK-N-SH Cells were transfected with NUB1-FLAG, HA-FAT10 and Myc-AIPL1
vectors in the presence and absence of the proteasome inhibitor MG132, as indicated. Cell lysates were harvested 24 hours post-transfection and
immunoprecipitates were analyzed by immunoblotting to detect the protein indicated. (A) NUB1 interacts with FAT10 and accelerates the
degradation of free FAT10 and FAT10-modified proteins. The change in levels of FAT10 was measured from 3 independent experiments (n = 3) of
duplicate samples. Heavy (h) and light (l) immunoglobulin chains are indicated. (B) NUB1 co-precipitates with AIPL1. (C) AIPL1 enhances the steady-
state levels of free FAT10 and FAT10 modified proteins, both alone and in the presence of NUB1. The change in levels of FAT10 was measured from 5
independent experiments (n = 5) of duplicate samples. (D) HA-FAT10 was visualised by immunocytochemical analysis with anti-HA and Cy2-
conjugated secondary antibody. NUB1-mediated degradation of FAT10 is altered by the presence of AIPL1. Scale bar is 20 mM. (C) and (E) A small
proportion of AIPL1 is itself covalently modified with FAT10, as detected by anti-HA, anti-AIPL1 and anti-FAT10 (rabbit polyclonal) antibodies. The
percentage of AIPL1 modified by FAT10 was measured from 3 independent experiments (n = 3). Conjugation of FAT10 to AIPL1 is prevented using a
FAT10 diglycine deletion mutant. The position of molecular weight markers is indicated in kilodalton (kDa).
doi:10.1371/journal.pone.0030866.g001
AIPL1 Regulates the FAT10 Pathway
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4 hours (,20% (24%67) FAT10-DHFR levels remaining) of
CHX treatment, demonstrating that AIPL1 significantly delayed
the degradation of FAT10-DHFR in the presence of NUB1
(p,0.050, Wilcoxon signed-rank test; 2 h CHX treatment)
(Figure 4B). In order to investigate whether the ability of AIPL1
to delay the NUB1-mediated degradation of FAT10-DHFR was
relevant to LCA pathogenesis, the ability of the AIPL1 mutants
A197P, C239R and G262S to hinder degradation of FAT10-
DHFR was assessed. The AIPL1 mutants A197P and C239R, but
not G262S, were defective in the ability to antagonise the
degradation of FAT10-DHFR by NUB1 (Figure 4C). Because
AIPL1 binds to both FAT10 and NUB1 to form a ternary
complex, the ability of AIPL1 to act against the NUB1-mediated
degradation of FAT10-DHFR could be related to its binding to
NUB1 or FAT10-DHFR. To address this issue, NUB1 was
expressed with wild type and mutant AIPL1 and their interaction
was investigated by co-precipitation. Wild type and the AIPL1
G262S mutant efficiently co-precipitated NUB1. By contrast, the
AIPL1 mutants A197P and C239R displayed severely reduced
interactions with NUB1 (Figure 4D). Moreover, wild type AIPL1
and the mutants A197P, C239R and G262S were still competent
in binding to FAT10-DHFR (Figure 4E). This suggests that the
ability of AIPL1 to block the degradation of FAT10 substrates is
dependent on the interaction of AIPL1 with NUB1, but not the
FAT10 substrate.
AIPL1 interacts with the FAT10 E1 activating enzyme
UBA6
The finding that AIPL1 binds to FAT10 and FAT10-modified
proteins in addition to associating with NUB1 to antagonise
degradation of a FAT10 model substrate led us to address whether
AIPL1 may also interact with other components of the FAT10
conjugation system, specifically the E1 activating enzyme UBA6.
His6-tagged UBA6 was co-expressed with FAT10 and led to a
dramatic increase in high molecular weight FAT10-conjugated
proteins as detected by western blot analysis (Figure 5A), consistent
with its role as the FAT10 E1 activating enzyme. In addition, the
levels of the AIPL1-FAT10 covalent conjugate were enhanced by
UBA6 expression (Figure 5A). Interestingly, expression of AIPL1
altered the profile of high molecular weight FAT10 conjugates
caused by UBA6 expression (Figure 5A), whereby several discrete
FAT10-conjugate bands, including increased FAT10-modified
AIPL1 (,72 kDa) and additional bands of ,82, 90 and 100 kDa,
predominated over the characteristic FAT10 smear. Co-precipi-
tation experiments revealed that UBA6 and AIPL1 were present in
the same complex (Figure 5B), and because AIPL1 also interacts
with FAT10 (Figure 2), we tested the effect of FAT10 expression
on the interaction between AIPL1 and UBA6. Interestingly,
FAT10 expression reduced the interaction between UBA6 and
AIPL1 (Figure 5C), suggesting FAT10 and UBA6 may compete
for a similar binding site on AIPL1.
Discussion
The proteasome regulator NUB1 was identified as an
interacting partner of the inherited blindness protein AIPL1 in a
yeast two-hybrid screen [6], suggesting AIPL1 may influence
retinal protein degradation pathways through modulating NUB1
function. The data presented here demonstrate that AIPL1
interacts with FAT10/FAT10-modified proteins, and acts to delay
the NUB1-mediated degradation of a model FAT10 substrate. In
addition, AIPL1 was shown to interact with the FAT10 E1
activating enzyme UBA6, which alongside its interaction with
NUB1 and FAT10 suggest involvement of AIPL1 in the regulation
of FAT10 function in the retina.
NUB1 was originally discovered due to its ability to interact
with and promote the proteasomal degradation of NEDD8 and
NEDD8-modified proteins [8], and subsequently was found also to
have the same effect on FAT10 and FAT10-modified proteins [7].
As NUB1 was shown to accelerate the degradation of FAT10 four-
fold more efficiently than NEDD8 [7], we tested if AIPL1 could
affect the NUB1-mediated proteasomal degradation of FAT10y-
Figure 2. AIPL1 binds to FAT10 and FAT10-modified proteins.
(A) Monomeric FAT10 co-precipitates with AIPL1 from transfected SK-N-
SH cell lysates. Cells were transfected with the indicated constructs and
immunoprecipitation was performed followed by immunoblot analysis.
(B) Recombinant purified GST-AIPL1 but not GST can pull down free
FAT10 and FAT10-conjugated proteins from HA-FAT10-transfected cell
lysates. (C) Recombinant purified GST-AIPL1, but not GST, pulls down
recombinant purified His6-FAT10. The position of molecular weight
markers is indicated in kilodalton (kDa).
doi:10.1371/journal.pone.0030866.g002
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lated proteins. AIPL1 increased the steady-state levels of both
monomeric FAT10 and FAT10-conjugated proteins in the
presence of NUB1, suggesting it acts against NUB1-mediated
proteasomal degradation of FAT10 substrates. Indeed, NUB1-
mediated degradation of the model FAT10 substrate FAT10-
DHFR was delayed in the presence of AIPL1. Furthermore, the
pathogenic AIPL1 mutants A197P and C239R were both
impaired in their ability to antagonise NUB1-mediated degrada-
tion, suggesting this function of AIPL1 may be relevant to LCA
pathogenesis. While A197P and C239R cause LCA, the disease-
causing status of G262S is less certain and this mutant was
previously found not to be defective in a functional assay for
NUB1 interaction and subcellular targeting [9,27]. Consistent
with these earlier findings, the AIPL1 mutants A197P and C239R,
but not G262S, were defective in the ability to antagonise the
degradation of FAT10-DHFR by NUB1. Interestingly, while the
A197P and C239R mutants could still interact with FAT10-
DHFR, they no longer interacted with NUB1, suggesting the
antagonism of NUB1 function requires the direct binding of
AIPL1 to NUB1. NUB1 is believed to be a facilitator of
proteasomal degradation, whereby interactions between NUB1’s
UBL domain and the proteasome are essential for FAT10
degradation, possibly through inducing a conformational change
in the 19S proteasome [15]. Therefore, the effects of AIPL1 on
NUB1-mediated degradation may occur through AIPL1 binding
to NUB1 and preventing NUB1 from productively associating
with the proteasome to facilitate FAT10 degradation. Mutations
that prevent association of AIPL1 with NUB1 and lose this ability
may, therefore, contribute to disease by failing to prevent or delay
the degradation of important, as yet undiscovered specific retinal
FAT10 substrates.
Our data suggest that AIPL1, NUB1 and FAT10 form a ternary
complex. In agreement with previously published work [27], we
found that the C239R mutant of AIPL1 cannot bind NUB1.
Figure 3. AIPL1, FAT10 and NUB1 form a ternary complex. Cells were transfected with constructs as indicated followed by
immunoprecipitation and immunoblot analysis. (A) AIPL1 and FAT10 both co-precipitate with NUB1 (top panel); NUB1 and FAT10 both co-
precipitate with AIPL1 (bottom panel). MG132 increased FAT10 steady-state levels and the amount of co-precipitated AIPL1 (top panel) or NUB1
(bottom panel). (B) NUB1 and AIPL1 both co-precipitate with FAT10. The AIPL1 C239R pathogenic mutant immunoprecipitated FAT10, but did not
affect its NUB1-mediated degradation profile. (C) The AIPL1 C239R mutant did not immunoprecipitate NUB1 but FAT10 expression promoted their
interaction. Heavy (h) and light (l) immunoglobulin chains are indicated. The position of molecular weight markers is indicated in kilodalton (kDa).
doi:10.1371/journal.pone.0030866.g003
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However, the presence of FAT10, which interacts with both
AIPL1 C239R and NUB1, restores the ability of AIPL1 to co-
precipitate NUB1, confirming the formation of a ternary complex.
The binding site of AIPL1 on NUB1 has been reported to be C-
terminal to the third UBA domain [27], consistent with the ability
of NUB1 to simultaneously bind FAT10 and AIPL1. It is possible
that FAT10 binds to NUB1 and AIPL1 through its distinct UBL
domains to complete the ternary complex, although the precise
binding interfaces between FAT10 and both NUB1 and AIPL1
remain to be determined. As the AIPL1 C239R mutant was able
to interact with FAT10-DHFR, but not to antagonise its NUB1-
mediated degradation, it is unclear what role the direct interaction
between AIPL1 and FAT10 substrate plays in the ternary
complex. One possibility is that AIPL1 may bind newly
FAT10ylated substrates prior to their association with NUB1,
thus preventing inappropriate NUB1-mediated degradation of the
FAT10 substrate. It may be possible that a ternary complex would
then exist until an appropriate signal initiates dissociation of
AIPL1 to permit NUB1-mediated degradation of the FAT10
substrate, or release of the modified protein and removal of
FAT10 by as-yet unidentified FAT10-specific proteases. Expand-
ing the latter hypothesis is the possibility that FAT10 plays
additional roles to protein degradation similar to other UBLs,
whereby it may act as a signalling or subcellular localisation
molecule. In this case, protection of the FAT10-modified protein
from NUB1-mediated degradation by AIPL1 would be important
for correct sorting or functional modulation of the modified
protein. In any case, the future identification of retinal FAT10
substrates will allow a greater investigation into the role of AIPL1
and NUB1 in determining their fate.
AIPL1 has previously been shown to be essential for the
biogenesis of rod PDE6 [2,3,4], and may cooperate with members
Figure 4. AIPL1 interacts with NUB1 to block the degradation of FAT10-DHFR. Cells were transfected with the indicated constructs, then
treated 24 hours later with cycloheximide (CHX) to block protein synthesis and assess degradation of FAT10-DHFR over the indicated times. (A) AIPL1
blocked the NUB1-mediated degradation of FAT10-DHFR, and the effect was stronger in the presence of MG132. (B) AIPL1 delayed the degradation of
FAT10-DHFR in the presence of NUB1. The percentage of FAT10 remaining was measured from 3 independent experiments (n = 3), and the level of
significance calculated using the Wilcoxon signed-rank test. (C) Pathogenic AIPL1 mutants A197P and C239R were defective in blocking FAT10-DHFR
degradation, while the G262S mutant was able to block degradation. (D) NUB1 co-precipitated with both WT and G262S AIPL1, but not with the
A197P or C239R mutants. (E) FAT10-DHFR co-precipitated with WT AIPL1, and the mutants A197P, C239R and G262S.
doi:10.1371/journal.pone.0030866.g004
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of the Hsp70 and Hsp90 chaperone machineries to perform this
function [5]. In the absence of AIPL1, PDE6 subunits are rapidly
degraded by the proteasome [3], so it is plausible that certain
PDE6 subunits may be direct substrates of FAT10ylation whose
NUB1-mediated degradation is normally hindered by AIPL1. This
scenario may fit with AIPL1 being involved in PDE6 quality
control, whereby NUB1-mediated degradation of fully folded
mature PDE6 is blocked by AIPL1, followed by removal of the
FAT10 signal by unidentified FAT10-specific proteases, while any
misfolded subunits would fail the quality control and be degraded.
However, there is currently no evidence that PDE6 can be
modified with FAT10, which could possibly reflect transient
modification and rapid degradation or removal of FAT10.
Alternatively, the role of AIPL1 in the FAT10 degradation
pathway may represent a separate function of AIPL1, unrelated to
its role as a specialised PDE6 chaperone.
In addition to delaying the degradation of a model FAT10
substrate, AIPL1 also co-precipitated the FAT10 E1 activating
enzyme UBA6. Coupled to the fact that UBA6 enhanced the
AIPL1-FAT10 covalent conjugate, this suggested AIPL1 may act
as a non-canonical E2 conjugating enzyme in photoreceptors,
whereby the FAT10-modification of AIPL1 may be via a thioester
linkage. However, individually mutating all seven cysteine residues
in AIPL1 did not abrogate the formation of the AIPL1-FAT10
conjugate and recombinant purified GST-AIPL1 was unable to
form a thioester with FAT10 in the presence of recombinant E1
activating enzyme GST-UBA6 in vitro (data not shown), arguing
against this possibility. Further work is therefore needed to
establish exactly the nature of AIPL1’s interaction with UBA6. It is
possible that AIPL1 co-operates closely with the FAT10ylation
machinery before it non-covalently binds to the new FAT10-
modified substrate, protecting the substrate from NUB1-mediated
degradation until appropriate spatial and temporal signals are
received, for example, in the developing retina. Indeed, FAT10
itself is known to be cell cycle regulated [28], suggesting tight
regulation of degradation of FAT10 substrates throughout the cell
cycle is important. However, no E3 ligases or physiological
substrates other than USE1 have thus far been reported in the
literature to allow a more detailed investigation of the role of
AIPL1 in this regard.
AIPL1 is only the fourth reported FAT10-interacting protein,
after the spindle checkpoint protein MAD2 [17], NUB1 [7] and
the histone deacetylase HDAC6 [21], and this is the first report to
demonstrate that the FAT10 pathway is associated with inherited
blindness. Interestingly, the association of FAT10 with HDAC6
occurred only upon proteasome inhibition, and caused microtu-
bule-dependent recruitment of FAT10 to aggresomes, thus
implicating FAT10 in lysosomal degradation pathways in addition
to NUB1-mediated proteasomal degradation [21]. By contrast, the
interaction of FAT10 with MAD2, which only occurred during
mitosis, further suggested FAT10 involvement in the cell cycle
[22]. In addition, FAT10 overexpression prevented the association
of MAD2 with kinetochores and increased aneuploidy in HCT116
cells [22], evidence of a non-degradative role of FAT10. It would
be interesting to test if the association of FAT10 and MAD2 could
be regulated by AIPL1, which would have implications for cell
cycle regulation in the developing photoreceptor.
The finding that AIPL1 appears to have a broad role in
regulating the FAT10 pathway expands the role of AIPL1 as a
specialised PDE6 chaperone to also having involvement in
photoreceptor protein degradation pathways. The fact that
mutations of AIPL1 were defective in antagonising NUB1-
mediated degradation of a model FAT10 substrate imply this
function of AIPL1 may be important in the pathogenesis of LCA.
Further studies are required to find physiological retinal substrates
for FAT10 modification, which will allow a more extensive
characterisation of the role of AIPL1 in regulating the FAT10
pathway. In addition, the identity of these physiological substrates
and how they are handled by AIPL1 prior to or as an alternative to
degradation will lead to new insights in photoreceptor function, as
well as expand our knowledge of the role of the FAT10 pathway in
human biology.
Figure 5. The FAT10 E1 activating enzyme interacts with AIPL1.
Cells were transfected as indicated and subject to immunoprecipitation
and immunoblot analysis. (A) Expression of the FAT10 E1 activating
enzyme UBA6 increases the amount of FAT10-conjugated proteins
including the covalent AIPL1-FAT10 conjugate. AIPL1 altered the profile
of UBA6-dependent FAT10 conjugation. (B) UBA6 co-precipitated with
AIPL1. (C) Co-precipitation of UBA6 with AIPL1 is abrogated in the
presence of FAT10. The position of molecular weight markers is
indicated in kilodalton (kDa).
doi:10.1371/journal.pone.0030866.g005
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